Article
Lakeland, Fla. — Molecular staging of melanoma can identify patients with missed micrometastatic disease, offering them the chance to receive more aggressive treatment, thus offering them the best chance of survival.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.